Day One Biopharmaceuticals — named for the conversations clinicians have with parents when they first tell them their child has cancer and how they hope to treat it — announced on Thursday its first financing and its first drug candidate. Backed by $60 million from Canaan, Access Biotechnology, and Atlas Venture, the 25-person startup has struck a deal with Takeda Pharmaceutical (TAK) to acquire the rights to develop TAK-580, including certain rights previously licensed by Takeda from Sunesis Pharmaceuticals (SNSS).